Compare abrdn Income Credit Strategies Fund (ACP) vs Cytokinetics Inc (CYTK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
abrdn Income Credit Strategies Fund vs Cytokinetics Inc — how do they compare? abrdn Income Credit Strategies Fund trades at $5.15 (market cap $641.16M), while Cytokinetics Inc trades at $77.07 (market cap $10.63B). The key difference: Cytokinetics Inc is far larger — about 16.6× abrdn Income Credit Strategies Fund's market cap, and abrdn Income Credit Strategies Fund pays a 18.2% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| ACP | CYTK | |
|---|---|---|
Market Cap | $641.16M | $10.63B |
Sector | Financials | Technology |
52-Week High | $5.98 | $87.26 |
52-Week Low | $5.01 | $34.31 |
Dividend Yield | 18.2% | — |
Enterprise Value | — | $10.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACP trades at $5.14, up 1.18% today, with a bearish technical signal from moving averages. The stock shows a low P/E of 7.74 and P/B of 0.9, indicating potential undervaluation, while a high net income margin of 95.31% and consistent dividend payments highlight financial strength. Recent news confirms dividend declarations for 2026.
The outlook is mixed; attractive valuation and dividends offer opportunity, but volatile revenue, an unsustainable distribution rate flagged by analysts, and high leverage pose significant risks. Investor sentiment is cautious due to these fundamental concerns.
CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.
The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end investment management company. Its primary goal is to generate high current income, with capital appreciation as a secondary objective. The fund mainly invests in debt and loan instruments from issuers across various industries and regions.
Read more on ACP →About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →
